Drug Development
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.
A preprint in bioRxiv from Penn State showed SARS-CoV-2 was detected in 33% (94) of the 283 white-tailed deer tested in Iowa between November 23, 2020 and January 10, 2021.
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones from this week.
The U.S. CDC has issued new travel warnings as surges of COVID-19 continue throughout the country and the world. For that and other COVID-19 news, read below.
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
If you are wondering what the butterfly effect is and how it affects COVID-19 patients, you have come to the right place. Here is everything you need to know.
Even before the drug’s approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA-E), or cerebral edema, observed in the trials.